Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir
Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We ai...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Willemse, S.B. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
Interferon-gamma-inducible protein-10 (IP-10) |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN - Hanief, M. ELSEVIER, 2015transfer abstract, a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:131 ; year:2016 ; pages:148-155 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.antiviral.2016.05.002 |
|---|
| Katalog-ID: |
ELV029547458 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV029547458 | ||
| 003 | DE-627 | ||
| 005 | 20230623201710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.antiviral.2016.05.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016005000005.pica |
| 035 | |a (DE-627)ELV029547458 | ||
| 035 | |a (ELSEVIER)S0166-3542(16)30044-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 670 |q VZ |
| 082 | 0 | 4 | |a 530 |q VZ |
| 082 | 0 | 4 | |a 660 |q VZ |
| 082 | 0 | 4 | |a 000 |a 150 |q VZ |
| 084 | |a 54.74 |2 bkl | ||
| 100 | 1 | |a Willemse, S.B. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir |
| 264 | 1 | |c 2016 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. | ||
| 650 | 7 | |a Adefovir |2 Elsevier | |
| 650 | 7 | |a Interferon-gamma-inducible protein-10 (IP-10) |2 Elsevier | |
| 650 | 7 | |a Intrahepatic IP-10 mRNA expression |2 Elsevier | |
| 650 | 7 | |a Combination therapy |2 Elsevier | |
| 650 | 7 | |a HBV |2 Elsevier | |
| 650 | 7 | |a Peginterferon |2 Elsevier | |
| 700 | 1 | |a Jansen, L. |4 oth | |
| 700 | 1 | |a de Niet, A. |4 oth | |
| 700 | 1 | |a Sinnige, M.J. |4 oth | |
| 700 | 1 | |a Takkenberg, R.B. |4 oth | |
| 700 | 1 | |a Verheij, J. |4 oth | |
| 700 | 1 | |a Kootstra, N.A. |4 oth | |
| 700 | 1 | |a Reesink, H.W. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Hanief, M. ELSEVIER |t Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN |d 2015transfer abstract |d a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research |g Amsterdam [u.a.] |w (DE-627)ELV012905879 |
| 773 | 1 | 8 | |g volume:131 |g year:2016 |g pages:148-155 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.antiviral.2016.05.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 54.74 |j Maschinelles Sehen |q VZ |
| 951 | |a AR | ||
| 952 | |d 131 |j 2016 |h 148-155 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s w sw |
|---|---|
| matchkey_str |
willemsesbjansenldenietasinnigemjtakkenb:2016----:nrhptcp0ranpami1lvlarsosmrefrbapstvcrnceaiibains |
| hierarchy_sort_str |
2016 |
| bklnumber |
54.74 |
| publishDate |
2016 |
| allfields |
10.1016/j.antiviral.2016.05.002 doi GBVA2016005000005.pica (DE-627)ELV029547458 (ELSEVIER)S0166-3542(16)30044-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl Willemse, S.B. verfasserin aut Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Elsevier Jansen, L. oth de Niet, A. oth Sinnige, M.J. oth Takkenberg, R.B. oth Verheij, J. oth Kootstra, N.A. oth Reesink, H.W. oth Enthalten in Elsevier Science Hanief, M. ELSEVIER Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN 2015transfer abstract a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research Amsterdam [u.a.] (DE-627)ELV012905879 volume:131 year:2016 pages:148-155 extent:8 https://doi.org/10.1016/j.antiviral.2016.05.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.74 Maschinelles Sehen VZ AR 131 2016 148-155 8 045F 610 |
| spelling |
10.1016/j.antiviral.2016.05.002 doi GBVA2016005000005.pica (DE-627)ELV029547458 (ELSEVIER)S0166-3542(16)30044-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl Willemse, S.B. verfasserin aut Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Elsevier Jansen, L. oth de Niet, A. oth Sinnige, M.J. oth Takkenberg, R.B. oth Verheij, J. oth Kootstra, N.A. oth Reesink, H.W. oth Enthalten in Elsevier Science Hanief, M. ELSEVIER Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN 2015transfer abstract a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research Amsterdam [u.a.] (DE-627)ELV012905879 volume:131 year:2016 pages:148-155 extent:8 https://doi.org/10.1016/j.antiviral.2016.05.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.74 Maschinelles Sehen VZ AR 131 2016 148-155 8 045F 610 |
| allfields_unstemmed |
10.1016/j.antiviral.2016.05.002 doi GBVA2016005000005.pica (DE-627)ELV029547458 (ELSEVIER)S0166-3542(16)30044-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl Willemse, S.B. verfasserin aut Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Elsevier Jansen, L. oth de Niet, A. oth Sinnige, M.J. oth Takkenberg, R.B. oth Verheij, J. oth Kootstra, N.A. oth Reesink, H.W. oth Enthalten in Elsevier Science Hanief, M. ELSEVIER Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN 2015transfer abstract a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research Amsterdam [u.a.] (DE-627)ELV012905879 volume:131 year:2016 pages:148-155 extent:8 https://doi.org/10.1016/j.antiviral.2016.05.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.74 Maschinelles Sehen VZ AR 131 2016 148-155 8 045F 610 |
| allfieldsGer |
10.1016/j.antiviral.2016.05.002 doi GBVA2016005000005.pica (DE-627)ELV029547458 (ELSEVIER)S0166-3542(16)30044-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl Willemse, S.B. verfasserin aut Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Elsevier Jansen, L. oth de Niet, A. oth Sinnige, M.J. oth Takkenberg, R.B. oth Verheij, J. oth Kootstra, N.A. oth Reesink, H.W. oth Enthalten in Elsevier Science Hanief, M. ELSEVIER Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN 2015transfer abstract a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research Amsterdam [u.a.] (DE-627)ELV012905879 volume:131 year:2016 pages:148-155 extent:8 https://doi.org/10.1016/j.antiviral.2016.05.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.74 Maschinelles Sehen VZ AR 131 2016 148-155 8 045F 610 |
| allfieldsSound |
10.1016/j.antiviral.2016.05.002 doi GBVA2016005000005.pica (DE-627)ELV029547458 (ELSEVIER)S0166-3542(16)30044-4 DE-627 ger DE-627 rakwb eng 610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl Willemse, S.B. verfasserin aut Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir 2016 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Elsevier Jansen, L. oth de Niet, A. oth Sinnige, M.J. oth Takkenberg, R.B. oth Verheij, J. oth Kootstra, N.A. oth Reesink, H.W. oth Enthalten in Elsevier Science Hanief, M. ELSEVIER Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN 2015transfer abstract a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research Amsterdam [u.a.] (DE-627)ELV012905879 volume:131 year:2016 pages:148-155 extent:8 https://doi.org/10.1016/j.antiviral.2016.05.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.74 Maschinelles Sehen VZ AR 131 2016 148-155 8 045F 610 |
| language |
English |
| source |
Enthalten in Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN Amsterdam [u.a.] volume:131 year:2016 pages:148-155 extent:8 |
| sourceStr |
Enthalten in Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN Amsterdam [u.a.] volume:131 year:2016 pages:148-155 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Maschinelles Sehen |
| institution |
findex.gbv.de |
| topic_facet |
Adefovir Interferon-gamma-inducible protein-10 (IP-10) Intrahepatic IP-10 mRNA expression Combination therapy HBV Peginterferon |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN |
| authorswithroles_txt_mv |
Willemse, S.B. @@aut@@ Jansen, L. @@oth@@ de Niet, A. @@oth@@ Sinnige, M.J. @@oth@@ Takkenberg, R.B. @@oth@@ Verheij, J. @@oth@@ Kootstra, N.A. @@oth@@ Reesink, H.W. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012905879 |
| dewey-sort |
3610 |
| id |
ELV029547458 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029547458</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.antiviral.2016.05.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016005000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029547458</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0166-3542(16)30044-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">000</subfield><subfield code="a">150</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.74</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Willemse, S.B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adefovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Interferon-gamma-inducible protein-10 (IP-10)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intrahepatic IP-10 mRNA expression</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HBV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Peginterferon</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jansen, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Niet, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sinnige, M.J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takkenberg, R.B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verheij, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kootstra, N.A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reesink, H.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hanief, M. ELSEVIER</subfield><subfield code="t">Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN</subfield><subfield code="d">2015transfer abstract</subfield><subfield code="d">a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012905879</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:148-155</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.antiviral.2016.05.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.74</subfield><subfield code="j">Maschinelles Sehen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2016</subfield><subfield code="h">148-155</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Willemse, S.B. |
| spellingShingle |
Willemse, S.B. ddc 610 ddc 670 ddc 530 ddc 660 ddc 000 bkl 54.74 Elsevier Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir |
| authorStr |
Willemse, S.B. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012905879 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 670 - Manufacturing 530 - Physics 660 - Chemical engineering 000 - Computer science, information & general works 150 - Psychology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon Elsevier |
| topic |
ddc 610 ddc 670 ddc 530 ddc 660 ddc 000 bkl 54.74 Elsevier Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon |
| topic_unstemmed |
ddc 610 ddc 670 ddc 530 ddc 660 ddc 000 bkl 54.74 Elsevier Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon |
| topic_browse |
ddc 610 ddc 670 ddc 530 ddc 660 ddc 000 bkl 54.74 Elsevier Adefovir Elsevier Interferon-gamma-inducible protein-10 (IP-10) Elsevier Intrahepatic IP-10 mRNA expression Elsevier Combination therapy Elsevier HBV Elsevier Peginterferon |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l j lj n a d na nad m s ms r t rt j v jv n k nk h r hr |
| hierarchy_parent_title |
Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN |
| hierarchy_parent_id |
ELV012905879 |
| dewey-tens |
610 - Medicine & health 670 - Manufacturing 530 - Physics 660 - Chemical engineering 000 - Computer science, knowledge & systems 150 - Psychology |
| hierarchy_top_title |
Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012905879 |
| title |
Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir |
| ctrlnum |
(DE-627)ELV029547458 (ELSEVIER)S0166-3542(16)30044-4 |
| title_full |
Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir |
| author_sort |
Willemse, S.B. |
| journal |
Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN |
| journalStr |
Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science 000 - Computer science, information & general works 100 - Philosophy & psychology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
148 |
| author_browse |
Willemse, S.B. |
| container_volume |
131 |
| physical |
8 |
| class |
610 610 DE-600 670 VZ 530 VZ 660 VZ 000 150 VZ 54.74 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Willemse, S.B. |
| doi_str_mv |
10.1016/j.antiviral.2016.05.002 |
| dewey-full |
610 670 530 660 000 150 |
| title_sort |
intrahepatic ip-10 mrna and plasma ip-10 levels as response marker for hbeag-positive chronic hepatitis b patients treated with peginterferon and adefovir |
| title_auth |
Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir |
| abstract |
Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. |
| abstractGer |
Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. |
| abstract_unstemmed |
Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir |
| url |
https://doi.org/10.1016/j.antiviral.2016.05.002 |
| remote_bool |
true |
| author2 |
Jansen, L. de Niet, A. Sinnige, M.J. Takkenberg, R.B. Verheij, J. Kootstra, N.A. Reesink, H.W. |
| author2Str |
Jansen, L. de Niet, A. Sinnige, M.J. Takkenberg, R.B. Verheij, J. Kootstra, N.A. Reesink, H.W. |
| ppnlink |
ELV012905879 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.antiviral.2016.05.002 |
| up_date |
2024-07-06T21:44:48.015Z |
| _version_ |
1803867691958665216 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV029547458</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623201710.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.antiviral.2016.05.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016005000005.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV029547458</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0166-3542(16)30044-4</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">670</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">660</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">000</subfield><subfield code="a">150</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.74</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Willemse, S.B.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Interferon-y–inducible protein-10 (IP-10), also called CXCL10, is produced by different types of cells such as monocytes, neutrophils and hepatocytes. IP-10 functions as an inflammatory cytokine, which after binding to its receptor CXCR3, expressed on T-lymphocytes, leads to immune activation. We aimed to establish if IP-10 expression in liver tissue and in plasma of chronic hepatitis B (CHB) patients correlated with each other and further to investigate if IP-10 levels before and during therapy with peginterferon and adefovir could predict treatment outcome in CHB patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Adefovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Interferon-gamma-inducible protein-10 (IP-10)</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intrahepatic IP-10 mRNA expression</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HBV</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Peginterferon</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jansen, L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Niet, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sinnige, M.J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Takkenberg, R.B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Verheij, J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kootstra, N.A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reesink, H.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Hanief, M. ELSEVIER</subfield><subfield code="t">Modeling and prediction of surface roughness for running-in wear using Gauss-Newton algorithm and ANN</subfield><subfield code="d">2015transfer abstract</subfield><subfield code="d">a multidisciplinary journal of antiviral agents, natural host defence mechanisms, interferons and antiviral vaccines : an official publication of the International Society for Antiviral Research</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012905879</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:131</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:148-155</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.antiviral.2016.05.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.74</subfield><subfield code="j">Maschinelles Sehen</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">131</subfield><subfield code="j">2016</subfield><subfield code="h">148-155</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4017324 |